Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.38 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.38 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL888001 | 0.92 | ADORA3 (0.45) | ADORA2AADORA2BADORA3P2RY12ADORA1 | |
| SCHEMBL7873199 | 0.91 | PRMT6 (0.40) | ADORA2APRMT6ADORA3P2RY12ADORA1 | |
| Hydroquinone SCHEMBL7070523 | 0.87 | PRMT6 (0.41) | ADORA2AADORA2BPRMT6ADORA3P2RY12 | |
| SCHEMBL4434106 | 0.87 | ADORA2A (0.39) | ADORA2AADORA2BPRMT6ADORA3P2RY12 | |
| SCHEMBL7075967 | 0.86 | ADORA2B (0.39) | ADORA2AADORA2BPRMT6ADORA3ADORA1 | |
| SCHEMBL6839735 | 0.85 | ADORA2A (0.43) | ADORA2AADORA2BPRMT6ADORA3ADORA1 | |
| SCHEMBL30901148 | 0.85 | ADORA2A (0.54) | ADORA2AADORA2BADORA3P2RY12ADORA1 | |
| SCHEMBL439196 | 0.85 | ADORA2A (0.54) | ADORA2AADORA2BADORA3P2RY12ADORA1 | |
| SCHEMBL21384845 | 0.83 | TYMP (0.48) | ADORA2AADORA2BPRMT6P2RY12 | |
| SCHEMBL2112014 | 0.83 | ADORA2A (0.48) | ADORA2AADORA2BADORA3ADORA1PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6169170-B1 | DUPLEX OLIGONUCLEOTIDE OF TWO COMPLEMENTARY STRANDS WHERE AT LEAST ONE STRAND HAS AT LEAST FIFTY PERCENT PHOSPHORAMIDATE LINKAGES AND AT LEAST TWO LINKAGES ARE CONSECUTIVE; ANTISENSE AGENTS WITH INCREASED PHOSPHODIESTERASE RESISTANCE | LYNX THERAPEUTICS, INC. | 2001-01-02 | — | — | US | disclosed |
| EP-0754242-A4 | OLIGONUCLEOTIDE N3'-m(7)P5' PHOSPHORAMIDATES: SYNTHESIS AND COMPOUNDS; HYBRIDIZATION AND NUCLEASE RESISTANCE PROPERTIES | LYNX THERAPEUTICS INC (US) | 1997-06-11 | — | — | EP | disclosed |
| EP-0754242-A1 | OLIGONUCLEOTIDE N3'$m(7)P5' PHOSPHORAMIDATES: SYNTHESIS AND COMPOUNDS; HYBRIDIZATION AND NUCLEASE RESISTANCE PROPERTIES | LYNX THERAPEUTICS, INC. (US) | 1997-01-22 | — | — | EP | disclosed |
| WO-1995025814-A1 | OLIGONUCLEOTIDE N3'→P5' PHOSPHORAMIDATES: SYNTHESIS AND COMPOUNDS; HYBRIDIZATION AND NUCLEASE RESISTANCE PROPERTIES | LYNX THERAPEUTICS, INC. (US) | 1995-09-28 | — | — | WO | disclosed |